Sector Expert: Larry Biegelsen

Wells Fargo Securities



Recent Quotes

"An investment in the long-term future for INO is a solid investment choice."

— Biotech Research Group, Seeking Alpha (6/21/16)
more >

"We expect JNJ's drug pipeline to deliver accelerating growth."

— Larry Biegelsen, Wells Fargo Securities (3/1/13)
more >

"We expect upcoming catalysts to drive strong EW's Sapien sales growth."

— Larry Biegelsen, Wells Fargo Securities (1/28/13)
more >

"We expect JNJ's pipeline to deliver accelerating growth."

— Larry Biegelsen, Wells Fargo Securities (1/8/13)
more >

"JNJ's Xarelto still has the most indications among the three new anticoagulants."

— Larry Biegelsen, Wells Fargo Securities (12/31/12)
more >

"JNJ's Xarelto should capture the lion's share of the U.S. market."

— Larry Biegelsen, Wells Fargo Securities (11/2/12)
more >

"GARY showed favorable mortality rates with TAVI using EW's Sapien."

— Larry Biegelsen, Wells Fargo Securities (8/27/12)
more >

"MDT's Ardian represents a compelling, long term opportunity."

— Larry Biegelsen, Wells Fargo Securities (8/23/12)
more >



Due to permission requirements, not all quotes are shown.